publication date: Feb. 16, 2018

Clinical Roundup NCCN & ASCO provide joint guidance on side effects from checkpoint inhibitors

Guidelines developed collaboratively by the American Society of Clinical Oncology and the National Comprehensive Cancer Network offer clinicians recommendations for assessment and management of side effects related to immune checkpoint inhibitors.

There are already several checkpoint inhibitors approved by FDA for various cancers, including melanoma, Hodgkin lymphoma, and lung, liver, kidney, and bladder cancers. The use of checkpoint inhibitors is continuously expanding to more indications, along with the development of new checkpoint inhibitors and combinations.  

“With rapidly increasing use of immune checkpoint inhibitors, it is imperative that clinicians are knowledgeable about their unique toxicity profiles,” Clifford Hudis, ASCO CEO, said in a statement. “These new guidelines from ASCO and NCCN will help our community continue to provide the highest quality of care to all patients as they incorporate these agents into routine care.”

There are already several checkpoint inhibitors approved by FDA for various cancers, including melanoma, Hodgkin lymphoma, and lung, liver, kidney, and bladder cancers. And the use of checkpoint inhibitors is continuously expanding to more indications, along with the development of new checkpoint inhibitors and combinations.

“The real winners here are patients whose health care teams now have high quality, collaborative guidelines from ASCO and NCCN … Continue reading NCCN & ASCO provide joint guidance on side effects from checkpoint inhibitors

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.